||Edward Tobinick is a California physician who has invented novel treatment approaches for a variety of medical conditions with widespread unmet medical need[1,2,3]. These conditions include Alzheimer's Disease and other forms of dementia; several forms of severe back and neck pain (including sciatica and cervical radiculopathy); a variety of additional neurological disorders; and pain due to cancer metastasis to the spine. Common to all of these conditions is the central involvement of inflammatory processes. Through May 2007 Dr. Tobinick has been awarded twelve U.S. patents for these new methods of treatment. His published papers have been cited in more than 150 scientific articles from leading academic centers around the world. His scientific work has been presented at medical conferences both in the U.S. and abroad. Major academic medical centers are currently involved in collaborative research with him to investigate his unique methods designed to deliver large molecules across the blood-brain barrier. In 2007 the anti-TNF pilot study for Alzheimer's Disease conducted by Dr. Tobinick and his colleagues was recognized and cited by the prestigious Dana Alliance for Brain Initiatives in their Progress Report on Brain Research and by a review article discussing the therapeutic potential of TNF-alpha inhibition as a treatment strategy for Alzheimer's disease and other neurodegenerative diseases by Nigel Grieg from the National Institute on Aging, National Institutes of Health, and his colleagues. In 2008, a case-report he co-authored documenting rapid clinical improvement in a patient with dementia following perispinal administration of etanercept, a treatment method he invented, has received considerable interest[6, 7].
||Targeting Alzheimer's with Novel Therapeutics